Compare Biogen Inc (BIIB) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Fox Corp Class A — how do they compare? Biogen Inc trades at $204.36 (market cap $30.13B), while Fox Corp Class A trades at $61.75 (market cap $24.58B). The key difference: Biogen Inc is the larger of the two by market cap, and Fox Corp Class A pays a 0.93% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | FOXA | |
|---|---|---|
Market Cap | $30.13B | $24.58B |
Sector | Health | Media |
52-Week High | $216.63 | $76.11 |
52-Week Low | $128.93 | $48.79 |
Enterprise Value | $37.20B | $27.94B |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
FOXA stock trades at $61.69, down 2.74% today, amid a bullish technical setup with strong support at $60. The company reported robust Q4 2026 results, beating earnings estimates with $1.79 EPS versus $1.44 expected, driven by World Cup advertising and Tubi streaming growth. Revenue rose 28% year-over-year to $4.21 billion in the quarter. Analyst sentiment is evenly split between Buy and Hold ratings, with a consensus price target of $65.33.
The outlook remains positive given strong ad demand and digital momentum, but risks include higher sports costs and reliance on major events. Earnings growth and streaming execution are key catalysts for further upside, though valuation multiples appear reasonable with a P/E of 16.18.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
